Please login to the form below

Not currently logged in
Email:
Password:

Ablynx reshuffles its board again

Dr Bo Jesper Hansen resigns from the Belgium biotech's board

Dr Bo Jesper HansenAfter one month as Ablynx’s chairman of the board of directors, Dr Bo Jesper Hansen (pictured) has resigned from the position due to personal reasons.

Dr Hansen will be succeeded by Dr Russell Greig, who will also become a permanent representative of Greig Biotechnology Global Consulting.

Dr Greig has been non-executive director of Ablynx since 2012, and has been unanimously elected by the board to be the biotech’s new chairman.

To date he has served in various roles during his 28-year career at GlaxoSmithKline, where he most recently served as president for both GSK Pharmaceuticals and SROne, the venture arm of GSK.

Dr Edwin Moses, chief executive officer of Ablynx, said: “We are very fortunate to have a very suitable successor for Bo Jesper, allowing for an orderly transition at this time.

“Russell knows the company extremely well and will be an important asset during the next months.”

14th February 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics